The Chinese nuclear imaging market is expected to reach a market size of USD 747.80 million by 2024, with a forecast CAGR of 9.45 %.
• Recent years have seen significant growth in nuclear medicine and imaging application. Increasing bone disease and cancer prevalence in China, along with the diagnostic technological advances, is expected to drive market growth over the forecast period.
• The burden of cancer and mortality in China is high. According to the latest 2018 report published by the WHO, there were 4,285,033 new cases of cancer in China, including both sexes and all ages, whereas 2,865,174 deaths were reported. Government support also contributes in terms of funding to the growth of Chinas radiopharmaceutical market.
• However, there are some factors that hinder market growth, such as the shorter radiopharmaceutical half-life and the high cost of the techniques.
According to the reports scope, nuclear medicine imaging procedures are non-invasive and are usually painless medical tests that help physicians diagnose and evaluate medical conditions, with the exception of intravenous injections. These imaging tests use radiopharmaceutical or radiotracer materials.
The PET Equipment Segment is Estimated to Grow with a Significant CAGR
The PET equipment segment covers stand-alone PET, hybrid PET/CT, hybrid PET/MRI, PET infusion systems, and cyclotrons used to produce short-lived radioisotopes on site. A positron emission tomography PET scan is an imaging test that allows the doctor to detect diseases in ones body. A PET scan is majorly used in oncology applications. The China Society of Nuclear Medicine was established in 1980. Since then, nuclear medicine has been developed rapidly in China. According to the Chinese Society of Nuclear Medicine, in 2015, there were 240 PET/CT and six PET/MR equipment in China. This number increased to a total of 306 PET scanners in 2017. Additionally, there are more than 900 departments of nuclear medicine in China that are actively running, and about more than one million patients receive nuclear medicine imaging examinations, per year, across the country. Moreover, with the governments support, the Chinese nuclear imaging market is expected to grow, in the future.
The market includes major players, and these players are also focused on R&D to strengthen their market position. Over the past couple of years, the market has noticed technological developments on a large scale. Some of the market players are Bayer AG, Bracco Imaging SpA, Canon Inc., Cardinal Health Inc., CIRC, Curium Pharma, GE Healthcare, Global Medical Solutions Ltd, Koninklijke Philips NV, Siemens Healthineers and Yantai Dongcheng Pharmaceutical Group Co. Ltd.
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2 RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1. Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3 MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porters Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.4. SWOT Analysis
3.5. Y-O-Y Analysis
CHAPTER 4 MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Increase in cancer and cardiac disease prevalence
4.1.2. Increase of technological advances
4.1.3. Growth in nuclear medicine and imaging applications
4.2. Market Restraints & Challenges
4.2.1. High technology costs
4.2.2. Short half-life of radioactive medicinal products
4.3. Market Opportunities
4.4. Key Challenges
CHAPTER 5 CHINA NUCLEAR IMAGING MARKET – BY PRODUCT
5.2.1. Single Photon Emission Computed Tomography SPECT
5.2.2. Positron-emission Tomography PET
5.3.1. SPECT Radioisotopes
188.8.131.52. Technetium-99m TC-99m
184.108.40.206. Thallium-201 TI-201
220.127.116.11. Gallium Ga-67
18.104.22.168. Iodine I-123
22.214.171.124. Other SPECT Radioisotopes
5.3.2. PET Radioisotopes
126.96.36.199. Fluorine-18 F-18
188.8.131.52. Rubidium-82 RB-82
184.108.40.206. Other PET Radioisotopes
CHAPTER 6 CHINA NUCLEAR IMAGING MARKET – BY APPLICATION
6.2. SPECT Applications
6.2.4. Other SPECT Applications
6.3. PET Applications
6.3.4. Other PET Applications
CHAPTER 7 CHINA NUCLEAR IMAGING MARKET – BY COUNTRY
CHAPTER 8 CHINA NUCLEAR IMAGING MARKET - COMPANY PROFILE
8.1. Bayer AG
8.2. Bracco Imaging SpA
8.3. Canon Inc.
8.4. Cardinal Health Inc.
8.5. China Isotope & Radiation Corporation CIRC
8.6. Curium Pharma
8.7. GE Healthcare
8.8. Global Medical Solutions Ltd
8.9. Koninklijke Philips NV
8.10. Siemens Healthineers
CHAPTER 9 CHINA NUCLEAR IMAGING MARKET – COMPETITIVE LANDSCAPE
9.1. Market Share Analysis
9.2. Strategies adopted by top companies
9.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 10 MARKET INSIGHTS
10.1. Industry Experts Insights
10.2. Analysts Opinions
10.3. Investment Opportunities
CHAPTER 11 APPENDIX
11.1. List of Tables
11.2. List of Figures
Need More information
Why to choose PMR
PMR Market Research
Our syndicated research reports cover 50+ industry sectors offering you product and country wise breakup of the market along with niche data and insights that will help you make informed business decision. Our research is focused on the key segments of an industry that possess opportunities of growth.
- Industrial ...
- Business ....
- Consumer ....
- Peer ....
Planet Market Reports added Latest and detailed market study report that focuses on “China Nuclear Imaging Market" Which offers essential information based on fresh ideas into China Nuclear Imaging Market industry along with unique market analysis which covers current top Manufactures in China Nuclear Imaging Market, growth, Consumption Demand, challenges, Historical data, subjects wise Survey of each chapters, Regional Insights, and Advancing industry trends, which will help our clients to aim China Nuclear Imaging Market. In addition, the report helps the customers to get a brief idea about Future demand and specifications of products which ensures the driving long-term income and productivity of global market.